Literature DB >> 17660140

Seroprevalence of hepatitis B viral markers among freshmen--20 years after mass hepatitis B vaccination program in Taiwan.

Hsien-Cheng Chang1, Chung-Jen Yen, Yi-Chin Lee, Tai-Yuan Chiu, Chyi-Feng Jan.   

Abstract

BACKGROUND/
PURPOSE: The nationwide hepatitis B vaccination program in Taiwan was well known for its efficacy in reducing the carrier rate of hepatitis B and the morbidity and mortality of hepatitis B-related diseases among children. The aim of this study was to investigate the seroprevalence of hepatitis B 20 years after this program was implemented.
METHODS: A total of 7592 freshmen from one university in Northern Taiwan participated in this study during their school entry health exam in September 2003 and September 2004. Basic data including gender, birthday, family history and vaccination history of hepatitis B by self-reported questionnaire were collected. Hepatitis B serum markers, including hepatitis B surface antigen, antibody against hepatitis B surface antigen, and antibody against hepatitis B core antigen were all checked. The differences in the seroprevalence of hepatitis B between two groups of subjects born before July 1984 and after July 1984 were examined. Multiple logistic analyses were performed for identifying the odds ratio (OR) of family history and other variables for each hepatitis B serum marker.
RESULTS: Subjects born after July 1984 were found to have a lower rate of hepatitis B surface antigen of 2.2% (95% confidence interval [CI], 1.8-2.6%) vs. 7.4% (95% CI, 5.9-8.9%), and core antibody against hepatitis B of 6.7% (95% CI, 6.0-7.3%) vs. 23.5% (95% CI, 21.1-25.9%), but a higher rate of surface antibody against hepatitis B of 74.3% (95% CI, 73.2-75.4%) vs. 69.1% (95% CI, 66.5-71.7%) compared with those born before July 1984 (all p < 0.001). Subjects with a family history of hepatitis B had higher risk of being infected by hepatitis B (OR, 4.07; 95% CI, 3.18-5.12) and becoming carriers (OR, 7.26; 95% CI, 5.05-10.44) after adjustment for sex, age, birth year, and self-reported hepatitis B vaccination history.
CONCLUSION: The seroprevalence of hepatitis B surface antigen continued to decline 20 years after neonatal hepatitis B vaccination program. It is strongly recommended that those who have a family history of hepatitis B should receive early check-up of hepatitis B status after complete vaccination or closely follow up their hepatitis B status after neonatal hepatitis B vaccination.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17660140     DOI: 10.1016/S0929-6646(07)60001-1

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  8 in total

1.  Seroprevalence of hepatitis B and immune response to hepatitis B vaccination in Chinese college students mainly from the rural areas of western China and born before HBV vaccination integrated into expanded program of immunization.

Authors:  Xue-Yan Liao; Zhen-Zuo Zhou; Fu-Bang Wei; Han-Ning Qin; Yuan Ling; Rong-Cheng Li; Yan-Ping Li; Yi Nong; Kui-Xia Sun; Jie Li; Hui Zhuang
Journal:  Hum Vaccin Immunother       Date:  2013-09-09       Impact factor: 3.452

2.  Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China.

Authors:  Zhen-Zi Wang; Yu-Hua Gao; Wei Lu; Cun-Duo Jin; Ying Zeng; Ling Yan; Feng Ding; Tong Li; Xue-En Liu; Hui Zhuang
Journal:  Hum Vaccin Immunother       Date:  2016-11-22       Impact factor: 3.452

3.  The one year effects of three doses of hepatitis B vaccine as a booster in anti-HBs-negative children 11-15 years after primary immunization; China, 2009-2011.

Authors:  Jun Yao; Huan Shan; Yongdi Chen; Zheng-gang Jiang; Xue-wei Dai; Jing-jing Ren; Kai-jin Xu; Bing Ruan; Shi-gui Yang; Qian Li
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Impact and long-term protection of hepatitis B vaccination: 17 years after universal hepatitis B vaccination in Tunisia.

Authors:  H Chaouch; W Hachfi; I Fodha; O Kallala; S Saadi; A Bousaadia; F Lazrag; I Bougmiza; M Aouni; A Trabelsi; E Ben Jazia; A Letaief
Journal:  Epidemiol Infect       Date:  2016-08-18       Impact factor: 4.434

5.  Infection with hepatitis B virus carrying novel pre-S/S gene mutations in female siblings vaccinated at birth: two case reports.

Authors:  Ming-Wei Lai; Christopher S-H Yeh; Chau-Ting Yeh
Journal:  J Med Case Rep       Date:  2010-06-23

6.  GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals.

Authors:  Edgar T Overton; Somnuek Sungkanuparph; Michael Klebert; Michael Royal; Debra Demarco-Shaw; William G Powderly; Judith A Aberg
Journal:  Open Virol J       Date:  2011-10-14

7.  Impact of universal vaccination against hepatitis B: the italian model.

Authors:  Rosa Cristina Coppola; Angelo Meloni; Marcello Campagna
Journal:  Hepat Mon       Date:  2012-07-30       Impact factor: 0.660

Review 8.  Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis.

Authors:  Kate Whitford; Bette Liu; Joanne Micallef; J Kevin Yin; Kristine Macartney; Pierre Van Damme; John M Kaldor
Journal:  Bull World Health Organ       Date:  2018-05-14       Impact factor: 9.408

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.